AMLX Q2 2022 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMLXAmylyx Pharmaceuticals, Inc.

$1B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$54M

Net Income

-$54M

EPS (Diluted)

$-0.93

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$46M

Free Cash Flow

-$48M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$225M

Total Liabilities

$32M

Stockholders' Equity

$193M

Cash & Equivalents

$67M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$54M	-$19M	-191.9%
Net Income	-$54M	-$22M	-146.6%